Biotechnology company Anivive Lifesciences revealed on Wednesday the launch of two pre-clinical studies to further evaluate the in vivo efficacy, safety and the therapeutic potential of antiviral GC376 as both a treatment for COVID-19 and other coronavirus related diseases.
Earlier this year, the company has submitted a pre-Investigational New Drug (pIND) request for GC376 with the Food and Drug Administration (FDA) to advance the programme for use in humans. It has licensed the exclusive worldwide rights to GC376 from Kansas State University for use as a treatment in both humans and animals.
The company said GC376 is a novel, first-in-class, small molecule protease inhibitor with a favorable therapeutic index demonstrated in preclinical studies. A common feature of viruses in the picornavirus-like supercluster is a 3C or 3C-like protease responsible for viral replication. GC376 has been shown to be a potent inhibitor of this protease across all coronaviruses with a high therapeutic index.
In addition, the viruses in this family include human coronavirus 229E, transmissible gastroenteritis virus of swine (TGEV), murine hepatitis virus (MHV), bovine coronavirus (BCV), feline infectious peritonitis virus (FIPV), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome (MERS) as well as COVID-19 (SARS-CoV-2), concluded the company.
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma